Cataract surgery and lens implantationThe Implantable Miniature Telescope for macular degenerationLane, Stephen S.a,b; Kuppermann, Baruch D.c; Author Information aDepartment of Ophthalmology, University of Minnesota, Stillwater, Minnesota, USA bAssociated Eye Care, Stillwater, Minnesota, USA cDepartment of Ophthalmology, University of California, Irvine, California, USA Correspondence to Stephen S. Lane MD, Associated Eye Care, 232 N. Main Street, Stillwater, MN 55082, USA Tel: +1 651 275 3000; fax: +1 651 275 3099; E-mail: [email protected] Current Opinion in Ophthalmology 17(1):p 94-98, February 2006. | DOI: 10.1097/01.icu.0000193067.86627.a1 Buy Metrics Abstract Purpose of review The function is described of the Implantable Miniature Telescope, which is completing clinical development for bilateral end-stage macular degeneration, and 6-month results of the Phase II/III IMT002 prospective, multicenter study are presented. Multispecialty patient management and implications of the study's findings are discussed. Recent findings No medical treatments are currently available for bilateral end-stage age-related macular degeneration (atrophic or disciform scar age-related macular degeneration). The visual prosthetic device discussed in this update is implanted in the posterior chamber to reduce the impact of the scotomata on the patient's central vision. The goal of treatment is to improve the patient's ability to perform everyday activities and participate in roles and hobbies that impact their quality of life. Patients implanted with the device experienced clinically significant gains in visual acuity and quality of life at 6 months. In total, 89% gained two or more lines of best-corrected near or distance visual acuity. The device was generally safe and well tolerated. The surgical technique is important to minimize surgically related reduction in endothelial cell density. Summary This age-related macular degeneration visual prosthesis has been shown to improve visual acuity and quality of life for the bilateral end-stage age-related macular degeneration patient population that at present has no other acceptable options. Endothelial cell density from baseline to 6 and 12 months after device implantation was reduced due to trauma from the surgical procedure, but was compatible with a healthy cornea. Meticulous surgical technique and a comprehensive, multispecialty approach to preoperative and postoperative patient management are essential for successful outcomes. © 2006 Lippincott Williams & Wilkins, Inc.